The FDA has approved brexanolone specifically for treatment of adults with postpartum depression (PPD). Administered I.V., it can relieve severe signs and symptoms of PPD within days rather than weeks. This article discusses the benefits and risks of brexanolone as a treatment for PPD, including nursing considerations and patient teaching.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NURSE.0000657072.85990.5a | DOI Listing |
Publication Analysis
Top Keywords
postpartum depression
8
brexanolone treatment
8
treating postpartum
4
depression brexanolone
4
brexanolone fda
4
fda approved
4
approved brexanolone
4
treatment adults
4
adults postpartum
4
depression ppd
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!